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ScienceDirectThe feline and human immunodeficiency viruses (FIV and HIV)
target helper T cells selectively, and in doing so they induce a
profound immune dysfunction. The primary determinant of HIV
cell tropism is the expression pattern of the primary viral
receptor CD4 and co-receptor(s), such as CXCR4 and CCR5.
FIV employs a distinct strategy to target helper T cells; a high
affinity interaction with CD134 (OX40) is followed by binding of
the virus to its sole co-receptor, CXCR4. Recent studies have
demonstrated that the way in which FIV interacts with its
primary receptor, CD134, alters as infection progresses,
changing the cell tropism of the virus. This review examines the
contribution of the virus–receptor interaction to replication in
vivo as well as the significance of these findings to the
development of vaccines and therapeutics.
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Introduction
The genus Felis is thought to have emerged close to 6.2
million years ago, during the late Miocene epoch [1].
Genetically, domestic cats are indistinguishable from the
African wildcat, Felis sylvestris lybica, and archaeological
evidence confirms that the close relationship between cats
and humans was evident nearly 10 000 years ago in the
Middle East [2]. The Felis lineage has suffered invasions by
viruses from three subfamilies of the retroviridae; the spu-
mavirus FeFV (feline foamy virus), the gammaretrovirus
FeLV (feline leukaemia virus), and the lentivirus FIV
(feline immunodeficiency virus). Lentiviruses are endemic
Open access under CC BY license.Current Opinion in Virology 2013, 3:670–675 in Felidae species (reviewed in [3]) and appear to have
invaded species such as the American puma (P. concolor)
many thousands of years ago, prior to the spread of pumas
from South America to North America (10–12 000 years
ago, after the last ice age). In contrast, the absence of
lentiviruses from the majority of species closely related
to the domestic cat suggests a recent introduction and
spread subsequent to domestication. The relatively recent
spread of FIV through the domestic cat population and the
striking similarities between the pathogenesis of FIV in
cats, and of AIDS in HIV-infected individuals offers a
unique opportunity to compare the evolution of the
host–virus relationship and the development of immunity
to infection.
FIV targets CD4+ helper T cells via an initial high affinity
interaction between Env and CD134 (OX40) [4,5] and
a subsequent interaction with the chemokine receptor
CXCR4 [6,7]. Expression of CD134 in the cat is restricted
largely to activated CD4+ T cells [8]. Accordingly, FIV
infection of the cat results in a progressive depletion of
CD4+ helper T cells and the development of an AIDS-
like immune dysfunction. The ensuing immunodefi-
ciency manifests with chronic gingivitis and stomatitis,
anorexia, cachexia, neurological signs and an increased
incidence of malignancy.
Although the selective targeting of FIV to helper T cells
may be explained by the restricted expression pattern of
CD134, in early infection, the primary cellular targets for
the virus are not only CD4+ helper T cells, but also
monocytes. Later in infection the tropism of the virus
extends further to encompass both CD8+ T cells and B
cells (reviewed in [9]). CD134 was first described as a
surface antigen that was expressed almost exclusively on
CD4+ T cells [10], thus the extended tropism of FIV
during the course of infection would seem counter-intui-
tive. The development of antibody reagents with which
the surface expression of feline CD134 may be measured,
confirmed the expression of CD134 on feline CD4+ T
cells [5,8] and monocyte-derived macrophages [8],
with lower levels of expression on a minor population
of activated CD8+ T cells and on CD45R+ (B220) B cells
[8] (Figure 1). The up-regulation of CD134 on feline
CD4+ T cells following activation [4,5], and the high
levels of surface expression achieved [8], are consistent
with the selective targeting of these cells in early in-
fection. While CD134 expression is ostensibly undetect-
able on feline peripheral blood (CD14+) monocytes,
weak expression can be detected on splenic macrophageswww.sciencedirect.com
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Restriction of feline CD134 expression to CD4+ T cells. CD134 expression was evaluated by flow cytometry on feline peripheral blood mononuclear
cells, setting analysis gates for either lymphocytes (L), monocytes (M) or neutrophils (N). While CD14 expression was restricted primarily to the
monocyte gate (upper left panel, green), CD134 expression (red) localised predominantly to the lymphocyte gate, coincident with the expression of
CD4 (upper right panel). Additional CD134 expression was evident in the neutrophil analysis gate, consistent with the reported expression of CD134 on
human neutrophils [43].in culture and is upregulated following activation with
lipopolysaccharide [8]. Although CD134 is expressed at
lower levels on macrophages than on activated CD4+
helper T cells, since macrophages are rich in CXCR4, a
scenario may be envisaged whereby following initial in-
fection and spread, the virus disseminates into compart-
ments where CD134 expression is a limiting factor,
principally cells of the monocyte/macrophage lineage,
and as yet uncharacterised subpopulations of B220+ B
cells and activated CD8+ T cells.
Not all FIVs bind CD134 in the same way
The primary determinant of the FIV Env–CD134 inter-
action has been mapped to the first cysteine-rich domain
(CRD1) of CD134 [11,12]. As human CD134 does not
mediate FIV infection [4] (one of the primary barriers
to the transmission of FIV from cats to humans), chi-
meric CD134 molecules based on human CD134 and
which bear the CRD1 of feline CD134 will support
infection with selected strains of FIV [11,12]. Indeed,
using this approach, a fully functional receptor for the
PPR strain of FIV could be reconstituted by exchanging
residues H45S, R59G, S60D, N62D, V64K in humanwww.sciencedirect.com CD134 [11]. Importantly, well-characterised patho-
genic strains of FIV, namely C-PGammer and GL8
(Glasgow-8) require additional determinants in the sec-
ond cysteine-rich domain (CRD-2) of CD134 for in-
fection [13]. C-PGammer was derived by serial
passage of plasma-borne virus during the acute phase
of infection [14] while GL8 was isolated from a cat
during a brief episode of illness during the protracted
latent period of infection (subsequently the cat lived for
a further eight years). Thus, these viruses are likely
representative of viruses that dominate in early infection
and, as such, may share properties with viruses that are
transmitted between cats in nature. Accordingly, C-
PGammer and GL8-like viruses may serve as biologi-
cally relevant challenge strains for trials of candidate
vaccines. The amino acid motif 78NYE80 at the crown
of a loop in CD134 CRD2 that participates in the
interaction between CD134 and its cognate ligand
(CD134L) is the essential determinant in CRD2 for
CD134-usage by C-PGammer and GL8 (Figure 2). That
GL8 and C-PGammer should be dependent upon
residues distal to the projected Env binding face on
CD134 is intriguing and may indicate that these virusesCurrent Opinion in Virology 2013, 3:670–675
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Residues critical to the function of feline CD134 as a receptor for FIV.
Binding and syncytium formation by CRD2-independent strains is
conferred upon human CD134 by inserting SER-45, GLY-59, ASP-60,
ASP-62 and LYS-64 from CRD1 (shown in green) into human CD134.
CRD2-dependent strains require additional determinants in CRD2, ASN-
78, TYR-79 and GLU-80 (shown in purple) for the receptor to function.
Structures were modelled by submitting feline CD134 and CD134L
sequences (AB128982 and DQ269941) to the SWISS-MODEL
automated protein modelling server [44].recognise a specific CD134 conformation that is sensi-
tive to the CD134L–CD134 interaction [15].
While the residues on CD134 that are important for FIV
Env binding have been described [11,12,13], the
corresponding receptor binding determinants on Env
are less well characterised. It is known that, with disease
progression, viral variants emerge which infect host cells
via a direct interaction with CXCR4 (CD134-indepen-
dent infection). Critical determinants of CD134-inde-
pendence reside in the V3-loop and single glutamate to
lysine mutations in residues 407 and 409 of V3 promote
CXCR4-dependent syncytium formation [16]. In vivo,
there is a strong selective pressure to restore a glutamate
residue at these positions and revert to virulence [16].
One of the driving forces for this reversion may be
escape from neutralising antibodies induced by
CD134-binding; a CD134-independent E407K mutant
of PPR was readily susceptible to CD134-dependent
neutralising antibodies [17].
Evolution of CD134 usage in vivo
The virus–receptor interaction is a major determinant of
the in vivo replicative capacity of HIV. For example, ex
vivo analyses of primary HIV-1 isolates revealed that viralCurrent Opinion in Virology 2013, 3:670–675 fitness mapped to the env gene [18,19]. Similarly, a
comparison of the envs from two primary isolates of
HIV-1 demonstrated that the reduced fitness associated
with a clade C Env was associated with weak cell surface
binding, inefficient entry, and an increased sensitivity to
CCR5 antagonists and fusion inhibitors [20]. Moreover,
HIV-1 clade B envelopes from early infection tend to
harbour amino acid signatures that favour efficient
expression of Env in infected cells, enhancing Env
incorporation into nascent virions and facilitating replica-
tion to a high titre [21,22]. These signature sequences are
lost during chronic infection under selective pressure
from the adaptive immune response [21,22]. In this con-
text, the requirement for the 78NYE80 motif within the
CRD2 of CD134 for both C-PGammer and GL8 Envs
may reflect a more efficient interaction between the
viruses and their receptors. While infection with C-
PGammer and GL8 is CRD2-dependent, strains such
as PPR and B2542 have no such requirement. We pos-
tulated that CRD2-dependent infection might represent
a feature of viruses that dominate ‘early’ in infection,
facilitating both transmission and infection. Following
establishment in the host, variants may then emerge that
have a reduced requirement for an interaction with CRD2
of CD134, and in some cases may even lose the require-
ment for CRD2-binding altogether (as in PPR and
B2542). This working hypothesis predicts that CRD2-
independent viruses will be more prevalent in the ‘late’
stage of infection. In order to test this hypothesis, the
receptor usage of viruses isolated six years post-infection
with a clonal preparation of the CRD2-dependent GL8
strain was examined [23]. While viral variants were
identified that remained near identical to the challenge
inoculum, additional variants were identified that dis-
played differences in the amino acid sequence of Env
that switched the viral phenotype to CRD2-independent.
Furthermore, these viruses displayed altered sensitivities
to antagonists of the Env–CD134 interaction. While GL8
was markedly CRD2-dependent, resistant to anti-CD134
antibody and soluble CD134L (sCD134L) and sensitive
to soluble CD134 (sCD134); variants that evolved in vivo
were highly sensitive to anti-CD134 antibody, sensitive
to sCD134L and resistant to sCD134 [23]. That ‘late’
variants of GL8 should be sensitive to inhibition by anti-
CD134 antibody is intriguing and may be significant,
given that autoantibodies against CD134 have been
detected in a proportion of FIV-infected cats [24] and
these autoantibodies were capable of blocking infection
with the CRD2-independent PPR strain of FIV [24].
Binding of the autoantibodies recognising CD134 in FIV
infected cats required pre-engagement of CD134 with
Env [24], reminiscent of the polyreactive CD4-induced
antibody 21c that recognises the HIV-1 Env–CD4 com-
plex and binds determinants on both Env and CD4 [25].
Polyclonal B cell activation is a feature of both FIV and
HIV infections and anti-CD4 autoantibodies have been
well documented in HIV infection. Whether anti-CD134www.sciencedirect.com
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response to antibodies raised against the viral Env protein
or are epiphenomena related to the generalised immune
dysregulation is unclear; nevertheless, the presence of
such antibodies in the sera of FIV-infected cats may have
the direct effect of suppressing the emergence of CRD2-
independent viruses.
Engagement of CD4+ T cell-expressed CD134 by anti-
gen presenting cell (APC)-expressed CD134L enhances
the expansion and survival of antigen-specific CD4+ T
cells (reviewed in [26]). Similarly, CD134L expressed on
CD4+ T cells may contribute to the maintenance of
CD4+ T cell longevity through T cell–T cell interactions
[27]. Accordingly, the FIV–CD134 interaction may influ-
ence profoundly the development of antigen-specific
immune responses as FIV will target preferentially the
very cells that have been triggered to expand in response
to infection, just as HIV infects HIV-specific CD4+ T
cells preferentially [28]. Whether, APC-expressed
CD134L, locally released soluble CD134 and CD134L,
or anti-CD134 autoantibodies influence viral entry and
expansion in vivo remains to be established. However, as
the CD134L–CD134 interaction is a prerequisite for the
expansion of antigen-specific CD4+ T cells, it would
seem likely that the virus would have evolved to associate
with the ligand bound form of CD134. Support for this
model comes from structural studies indicating that the
primary binding face for Env on CD134 is distinct from
the CD134L-binding face mapped by X-ray crystallogra-
phy [29]. Accessibility of the FIV Env binding site on the
ligand-engaged form of CD134 may facilitate the trans-
mission of FIV bound to the surface of dendritic cells
(through DC-SIGN [30]) to adjacent CD134-expressing
CD4+ T cells. However, as FIV infection is modulated by
engagement of CD134 by CD134L [15], a scenario may
also be envisaged in which the Env-CD134 interaction
modulates signalling through CD134. CD134-engage-
ment by CD134L recruits TNFR-associated factors
(TRAFs) to the cytoplasmic tail of the molecule and
triggers an NF-kB1-dependent signalling pathway; if
native Env acts as a CD134 agonist, viral attachment to
CD134 may promote the expansion and survival of the
very target cells required for FIV replication. Conversely,
if Env acts as an antagonist, attachment to CD134 may
contribute to the selective depletion of FIV-specific
CD4+ T cells.
CD134-usage and transmission
If CD134 CRD2-dependent infection is a signature of
FIV isolates from the ‘early’ stage of infection, such
‘early’ virus strains would appear to be the most appro-
priate targets for vaccine development. Assuming that
both CRD2-dependent and CRD2-independent viruses
are transmitted from an infected animal to a recipient
during biting, what happens to CRD2-independent
viruses following transmission? Are CRD2-independentwww.sciencedirect.com viruses filtered from the inoculum during the process of
transmission, analogous to the filtering of X4 variants of
HIV-1 as articulated in the ‘gatekeeper’ hypothesis
[31,32]? To resolve this question, a synthetic FIV qua-
sispecies was prepared comprising matched doses of six
clonal variants, identical in gag and pol but with unique
envs derived from either CRD2-dependent or indepen-
dent variants of FIV GL8. Following experimental trans-
mission of this reconstituted quasispecies to naive
animals, a selective expansion of CRD2-dependent
viruses was observed [33]. CRD2-independent viruses
failed to thrive in vivo, achieving lower proviral loads.
Further, the failure of the CRD2-independent viruses to
thrive was independent of early neutralising antibody or
cytotoxic T cell responses [33]. These data suggest that
CRD2-dependent viruses are able to replicate more effi-
ciently in the host. Thus, clear parallels exist between the
dominance of CCR5-dependent strains of HIV-1 and
CD134 CRD2-dependent strains of FIV during early
infection, culminating in the efficient targeting of a
specific CD4+ helper T cell population.
What drives the emergence of CD134 CRD2-
independent viruses?
The Fel-O-Vax FIV vaccine (Pfizer Inc.) combines inac-
tivated virus and inactivated cells with a proprietary
adjuvant. At the core of the vaccine is the FL4 strain
of FIV, a derivative of the prototypic (and CRD2-inde-
pendent) Petaluma isolate of FIV. The Env of FL4 is
curious in that it lacks two potential sites for N-linked
glycosylation that are highly conserved amongst the
majority of field strains of virus. The T271I and
N342Y mutations in FL4 lie in a loop region that is
similar in location to the V1V2 loop of HIV. When
identical mutations were incorporated into the Envs of
either GL8 or C-PGammer, receptor usage was switched
from CRD2-dependent to CRD2-independent [34].
Given the role of N-linked glycosylation in shielding
Env from the humoral immune response, the humoral
response to infection may offer a driving force for the
switch from CRD2-dependent to CRD2-independent
infection. Consistent with this hypothesis, viral variants
that emerged in vivo following infection with a clonal
preparation of GL8, and which resisted neutralisation by
homologous serum, displayed a shift in receptor usage
from CRD2-dependent to CRD-2 independent [23]. For
one variant, exchange of the hypervariable V5 loop of Env
alone was sufficient to render the virus both neutralising
antibody resistant and CRD2-independent [23]. As poly-
clonal sera elicited in infected cats can be remarkably
mono-specific, targeting single determinants in the vari-
able loops of the virus [35,36], in vivo escape from
neutralisation may be sufficient to drive the emergence
of CRD2-independent viruses. In doing so, the progeny
viruses may gain the ability to spread into additional
cellular compartments through a direct (CD134-indepen-
dent) interaction with CXCR4 [17].Current Opinion in Virology 2013, 3:670–675
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The replication of FIV in vivo may be influenced by both
host and viral factors; in this review we have focussed on
the Env–CD134 interaction. However, replication may
also be influenced by additional viral determinants; tran-
scriptional regulation by the long terminal repeats
(LTRs) and the accessory gene orfA [37–41] and the
ability of the virus to evade intrinsic immune factors such
as APOBEC proteins [38,42]. Given that the virus–re-
ceptor interaction is the initial event in retroviral replica-
tion, understanding the intricacies of the Env–CD134
relationship will inform future strategies for the devel-
opment of both FIV vaccines and therapeutics. Moreover,
as the lentiviruses of cats and humans have evolved two
distinct strategies to selectively target infection of CD4+
helper T cells, inter-species comparisons offer a unique
opportunity to discern what makes immunodeficiency-
causing lentiviruses tick.
Acknowledgements
This work was supported by funding from the Biotechnology and Biological
Sciences Research Council (BBSRC) and The Wellcome Trust to MJH and
BJW.
References and recommended reading
Papers of particular interest, published within the period of review,
have been highlighted as:
 of special interest
 of outstanding interest
1. Johnson WE, Eizirik E, Pecon-Slattery J, Murphy WJ, Antunes A,
Teeling E, O’Brien SJ: The late Miocene radiation of modern
Felidae: a genetic assessment. Science 2006, 311:73-77.
2. Driscoll CA, Clutton-Brock J, Kitchener AC, O’Brien SJ: The
taming of the cat. Genetic and archaeological findings hint
that wildcats became housecats earlier – and in a different
place – than previously thought. Sci Am 2009, 300:68-75.
3. Pecon-Slattery J, Troyer JL, Johnson WE, O’Brien SJ: Evolution
of feline immunodeficiency virus in Felidae: implications for
human health and wildlife ecology. Vet Immunol Immunopathol
2008, 123:32-44.
4.

Shimojima M, Miyazawa T, Ikeda Y, McMonagle EL, Haining H,
Akashi H, Takeuchi Y, Hosie MJ, Willett BJ: Use of CD134 as a
primary receptor by the feline immunodeficiency virus.
Science 2004, 303:1192-1195.
This publication describes the molecular cloning of the primary receptor for
FIV, CD134. CD134 is demonstrated to be essential for infection with
primary isolates of FIV and to be dependent on the co-expression of CXCR4.
5.

de Parseval A, Chatterji U, Sun P, Elder JH: Feline
immunodeficiency virus targets activated CD4+ T cells by
using CD134 as a binding receptor. Proc Natl Acad Sci U S A
2004, 101:13044-13049.
This publication demonstrates that feline CD134 is upregulated selec-
tively on CD4+ T cells and mediates FIV Env binding and viral infection.
Although FIV Env also bound to CD8+ T cells, this binding was CD134-
independent and did not mediate infection.
6. Willett BJ, Hosie MJ, Neil JC, Turner JD, Hoxie JA: Common
mechanism of infection by lentiviruses. Nature 1997, 385:
587.
7. Willett BJ, Picard L, Hosie MJ, Turner JD, Adema K,
Clapham PR: Shared usage of the chemokine receptor
CXCR4 by the feline and human immunodeficiency viruses.
J Virol 1997, 71:6407-6415.
8.

Willett BJ, McMonagle EL, Logan N, Spiller OB, Schneider P,
Hosie MJ: Probing the interaction between the felineCurrent Opinion in Virology 2013, 3:670–675 immunodeficiency virus and CD134 using a novel monoclonal
antibody 7D6 and CD134L (OX40L). J Virol 2007, 81:9665-9679.
This publication describes the development of a feline CD134-specific
monoclonal antibody with which the virus–receptor interaction could be
dissected. While CD134-expression was restricted primarily to activated
CD4+ T cells, low level expression could also be detected on a sub-
population of activated CD8+ T cells, B cells and monocytes, consistent
with the reported cell tropism of FIV in chronically infected cats.
9. Willett BJ, Hosie MJ: The felid immunodeficiency viruses: viral
cell tropism and the pathogenesis of feline AIDS. In
Lentiviruses and Macrophages. Edited by Desport M. Caister
Academic Press; 2010:231-250.
10. Mallett S, Fossum S, Barclay AN: Characterization of the MRC
OX40 antigen of activated CD4 positive T lymphocytes—a
molecule related to nerve growth factor receptor. EMBO J
1990, 9:1063-1068.
11.

de Parseval A, Chatterji U, Morris G, Sun P, Olson AJ, Elder JH:
Structural mapping of CD134 residues critical for interaction
with feline immunodeficiency virus. Nat Struct Mol Biol 2004,
12:60-66.
This publication describes the mapping of the FIV Env (SU) binding site on
feline CD134. By substituting amino acid residues in CRD1 of feline
CD134 with the corresponding residues from human CD134, the SU-
binding site on CD134 was mapped to an external loop on the opposite
face of the molecule to the CD134L binding site.
12.

Willett BJ, McMonagle EL, Bonci F, Pistello M, Hosie MJ: Mapping
the domains of CD134 as a functional receptor for feline
immunodeficiency virus. J Virol 2006, 80:7744-7747.
13.

Willett BJ, McMonagle EL, Ridha S, Hosie MJ: Differential
utilization of CD134 as a functional receptor by diverse strains
of feline immunodeficiency virus (FIV). J Virol 2006, 80:3386-
3394.
This publication demonstrates that isolates of FIV differ in the way they
interact with CD134. Isolates such as GL8, CPGammer and NCSU1 are
dependent of determinants in both CRD1 and CRD2 of CD134 while PPR
and B2542 are able to infect via an interaction with CRD1 alone. This
observation suggests the CD134–CD134L interaction may influence viral
infectivity while conversely, the Env–CD134 interaction may modulate
CD134-dependent expansion of antigen-dependent T cells.
14. Diehl LJ, Mathiason-Dubard CK, O’Neil LL, Obert LA, Hoover EA:
Induction of accelerated feline immunodeficiency virus
disease by acute-phase virus passage. J Virol 1995, 69:6149-
6157.
15.

Willett BJ, McMonagle EL, Logan N, Schneider P, Hosie MJ:
Enforced covalent trimerisation of soluble feline CD134
(OX40)-ligand generates a functional antagonist of feline
immunodeficiency virus. Mol Immunol 2009.
This publication describes the development of a stable trimeric form of
feline CD134L and its biological properties. CRD2-independent strains of
FIV were found to be more sensitive to inhibition by soluble trimeric
CD134L than CRD2-dependent strains, indicating that CRD2-dependent
strains may be capable of infecting cells in which CD134 exists in a ligand-
bound state.
16. Hosie MJ, Willett BJ, Klein D, Dunsford TH, Cannon C,
Shimojima M, Neil JC, Jarrett O: Evolution of replication
efficiency following infection with a molecularly cloned feline
immunodeficiency virus of low virulence. J Virol 2002, 76:6062-
6072.
17. Hu QY, Fink E, Elder JH: Mapping of receptor binding
interactions with the FIV surface glycoprotein (SU);
implications regarding immune surveillance and cellular
targets of infection. Retrovirology 2012, 2012:1-11.
18. Rangel HR, Weber J, Chakraborty B, Gutierrez A, Marotta ML,
Mirza M, Kiser P, Martinez MA, Este JA, Quinones-Mateu ME: Role
of the human immunodeficiency virus type 1 envelope gene in
viral fitness. J Virol 2003, 77:9069-9073.
19. Ball SC, Abraha A, Collins KR, Marozsan AJ, Baird H, Quinones-
Mateu ME, Penn-Nicholson A, Murray M, Richard N, Lobritz M
et al.: Comparing the ex vivo fitness of CCR5-tropic human
immunodeficiency virus type 1 isolates of subtypes B and C.
J Virol 2003, 77:1021-1038.
20. Marozsan AJ, Moore DM, Lobritz MA, Fraundorf E, Abraha A,
Reeves JD, Arts EJ: Differences in the fitness of two diversewww.sciencedirect.com
FIV replication Willett and Hosie 675wild-type human immunodeficiency virus type 1 isolates are
related to the efficiency of cell binding and entry. J Virol 2005,
79:7121-7134.
21. Asmal M, Hellmann I, Liu WM, Keele BF, Perelson AS,
Bhattacharya T, Gnanakaran S, Daniels M, Haynes BF, Korber BT
et al.: A signature in HIV-1 envelope leader peptide associated
with transition from acute to chronic infection impacts
envelope processing and infectivity. PLoS ONE 2011:6.
22. Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, Hraber PT,
Lapedes AS, Shen TY, Gaschen B, Krishnamoorthy M, Li H et al.:
Recurrent signature patterns in HIV-1 B clade envelope
glycoproteins associated with either early or chronic
infections. PLoS Pathog 2011:7.
23.

Willett BJ, Kraase M, Logan N, McMonagle EL, Samman A,
Hosie MJ: Modulation of the virus–receptor interaction by
mutations in the V5 loop of feline immunodeficiency virus (FIV)
following in vivo escape from neutralising antibody.
Retrovirology 2010, 7:38.
This publication demonstrates that the humoral immune response to FIV
may exert a selective pressure on the emergence of CRD2-independent
viruses. Following in vivo infection with a clonal preparation of the CRD2-
dependent GL8 strain of FIV, viral variants arise that resist neutralisation
by homologous antibody and which are CRD2-independent. Resistance
to neutralisation and CRD2-independence map to mutations in the fifth
variable loop (V5) of Env.
24.

Grant CK, Fink EA, Sundstrom M, Torbett BE, Elder JH: Improved
health and survival of FIV-infected cats is associated with the
presence of autoantibodies to the primary receptor, CD134.
Proc Natl Acad Sci U S A 2009, 106:19980-19985.
This publication demonstrates the presence of anti-CD134 antibodies in
sera from FIV-infected cats. The anti-CD134 antibodies appear to bind to
a cryptic epitope on CD134 that is only revealed following SU-binding,
while the presence of the anti-CD134 antibodies appears to correlate with
lower viral loads.
25. Diskin R, Marcovecchio PM, Bjorkman PJ: Structure of a clade C
HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals
anti-CD4 polyreactivity. Nat Struct Mol Biol 2010, 17:608-613.
26. Croft M, So T, Duan W, Soroosh P: The significance of OX40 and
OX40L to T-cell biology and immune disease. Immunol Rev
2009, 229:173-191.
27. Soroosh P, Ine S, Sugamura K, Ishii N: OX40–OX40 ligand
interaction through T cell–T cell contact contributes to CD4 T
cell longevity. J Immunol 2006, 176:5975-5987.
28. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ,
Okamoto Y, Casazza JP, Kuruppu J, Kunstman K, Wolinsky S
et al.: HIV preferentially infects HIV-specific CD4+ T cells.
Nature 2002, 417:95-98.
29.

Compaan DM, Hymowitz SG: The crystal structure of the
costimulatory OX40–OX40L complex. Structure 2006,
14:1321-1330.
This publication describes the crystal structure of the CD134–CD134L
(OX40–OX40L) complex. CD134 and CD134L interact as trimers, the FIV
SU binding site localizes to the tip of CD134 CRD1 on the opposite face to
the CD134L binding site.
30. de Parseval A, Su SV, Elder JH, Lee B: Specific interaction of
feline immunodeficiency virus surface glycoprotein with
human DC-SIGN. J Virol 2004, 78:2597-2600.
31. Margolis L, Shattock R: Selective transmission of CCR5-
utilizing HIV-1: the ‘gatekeeper’ problem resolved? Nat Rev
Microbiol 2006, 4:312-317.
32. Grivel JC, Shattock RJ, Margolis LB: Selective transmission of
R5 HIV-1 variants: where is the gatekeeper? J Transl Med 2011,
9(Suppl 1):S6.www.sciencedirect.com 33.

Willett BJ, Kraase M, Logan N, McMonagle E, Varela M, Hosie MJ:
Selective expansion of viral variants following experimental
transmission of a reconstituted feline immunodeficiency virus
quasispecies. PLoS ONE 2013, 8:e54871.
This publication demonstrates that CRD2-independent strains of FIV are
at a replicative disadvantage following transmission. When a mixture of
CRD2-dependent and independent strains of virus are transmitted
experimentally, the CRD2-dependent strains expand preferentially in
vivo. These observations suggest that in order to prevent transmission,
vaccines should target CRD2-dependent strains of virus.
34.

Willett BJ, McMonagle EL, Logan N, Samman A, Hosie MJ: A
single site for N-linked glycosylation in the envelope
glycoprotein of feline immunodeficiency virus modulates the
virus–receptor interaction. Retrovirology 2008, 5:77.
This publication demonstrates that the virus-receptor interaction is sen-
sitive to the N-linked glycosylation of Env and that mutations in the V1/V2
loop homologue may shift the receptor interaction from CRD2-dependent
to CRD2-independent. Such mutations are rare in field isolates, but are
present in vaccine strains, indicating that deglycosylation of V1/V2 may
have arisen during the cultivation of the vaccine strains in vitro. Degly-
cosylation of V1/V2 may expose novel determinants on Env that con-
tribute to immunity to infection following vaccination.
35. Siebelink KHJ, Rimmelzwaan GF, Bosch ML, Meloen RH,
Osterhaus ADME: A single amino acid substitution in
hypervariable region 5 of the envelope protein of feline
immunodeficiency virus allows escape from virus
neutralisation. J Virol 1993, 67:2202-2208.
36. Samman A, Logan N, McMonagle EL, Ishida T, Mochizuki M,
Willett BJ, Hosie MJ: Neutralization of feline immunodeficiency
virus by antibodies targeting the V5 loop of Env. J Gen Virol
2010, 91:242-249.
37. Thompson J, MacMillan M, Boegler K, Wood C, Elder JH,
VandeWoude S: Pathogenicity and rapid growth kinetics of
feline immunodeficiency virus are linked to 30 elements. PLoS
ONE 2011, 6:e24020.
38. Troyer RM, Thompson J, Elder JH, Vandewoude S: Accessory
genes confer high replication rate of virulent feline
immunodeficiency virus (FIV). J Virol 2013.
39. Dean GA, Himathongkham S, Sparger EE: Differential cell
tropism of feline immunodeficiency virus molecular clones in
vivo. J Virol 1999, 73:2596-2603.
40. Pistello M, Moscardini M, Mazzetti P, Bonci F, Zaccaro L,
Isola P, Freer G, Specter S, Matteucci D, Bendinelli M:
Development of feline immunodeficiency virus ORF-A (tat)
mutants: in vitro and in vivo characterization. Virology 2002,
298:84-95.
41. Inoshima Y, Kohmoto M, Ikeda Y, Yamada H, Kawaguchi Y,
Tomonaga K, Miyazawa T, Kai C, Umemura T, Mikami T:
Roles of the auxiliary genes and AP-1 binding site in the
long terminal repeat of feline immunodeficiency virus
in the early stage of infection in cats. J Virol 1996,
70:8518-8526.
42. Munk C, Beck T, Zielonka J, Hotz-Wagenblatt A, Chareza S,
Battenberg M, Thielebein J, Cichutek K, Bravo IG, O’Brien SJ et al.:
Functions, structure, and read-through alternative splicing of
feline APOBEC3 genes. Genome Biol 2008, 9:R48.
43. Baumann R, Yousefi S, Simon D, Russmann S, Mueller C,
Simon HU: Functional expression of CD134 by neutrophils. Eur
J Immunol 2004, 34:2268-2275.
44. Schwede T, Kopp J, Guex N, Peitsch MC: SWISS-MODEL: an
automated protein homology-modeling server. Nucleic Acids
Res 2003, 31:3381-3385.Current Opinion in Virology 2013, 3:670–675
